# Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

> **NCT05687253** · PHASE2 · COMPLETED · sponsor: **Baudax Bio** · enrollment: 80 (actual)

## Conditions studied

- Neuromuscular Blockade
- Anesthesia
- Surgery

## Interventions

- **DRUG:** BX1000
- **DRUG:** Rocuronium Bromide

## Key facts

- **NCT ID:** NCT05687253
- **Lead sponsor:** Baudax Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-25
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-05-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05687253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05687253, "Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05687253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*